Lupus News and Research RSS Feed - Lupus News and Research

Systemic lupus erythematosus (SLE), also called lupus, is an autoimmune disorder characterized by the immune system attacking the body's own tissues and organs, leading to inflammation and damage. The severity of the disease varies, from mild cases only involving the skin to severe cases affecting multiple organs, including the brain. Lupus sufferers experience flares, or intervals of active disease, and remissions in disease. The disease most predominantly occurs in women of childbearing age, but also affects children, adolescents, and men. While the cause of lupus is still unknown, various genetic, environmental, and infectious causes have been associated with its development. Current treatments for lupus vary depending on the extent of the disease, and may change over time. Some medications used to ease symptoms include nonsteroidal anti-inflammatory drugs, antimalarial drugs, corticosteroids, and immunosuppressive medications, though many of these drugs carry their own risks.
Experts to discuss research on lupus at world congress organized by MedUni Vienna

Experts to discuss research on lupus at world congress organized by MedUni Vienna

Lupus is an autoimmune disease with so many different symptoms that it is often difficult to diagnose and to treat. Despite huge medical advances over the last few years, lupus is incurable. Modern, individually tailored therapeutic approaches are aimed at helping sufferers. The world congress organized by MedUni Vienna brings experts from more than 80 countries together in Vienna from 2 to 6 September to discuss the latest research results and therapies. [More]
ACR commends FDA’s draft guidance requiring distinct names for biosimilars, biologic therapies

ACR commends FDA’s draft guidance requiring distinct names for biosimilars, biologic therapies

The American College of Rheumatology (ACR) today praised the Food and Drug Administration (FDA) for issuing draft guidance requiring separate and distinct names for biosimilars and biologic therapies. [More]
Brain scans may help predict patients' response to antipsychotic drug treatment

Brain scans may help predict patients' response to antipsychotic drug treatment

Investigators at The Feinstein Institute for Medical Research have discovered that brain scans can be used to predict patients' response to antipsychotic drug treatment. The findings are published online in the latest issue of The American Journal of Psychiatry. [More]
Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans. [More]
Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus Biotherapeutics today announced that they have entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are an important class of proteins that play a key role in the innate immune system. [More]
Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). [More]
Allergan receives FDA approval to market 28 additional styles of Natrelle 410 silicone-filled breast implants

Allergan receives FDA approval to market 28 additional styles of Natrelle 410 silicone-filled breast implants

Allergan, plc. today announced that the company has received approval from the U.S. Food and Drug Administration to market 28 additional styles of Natrelle 410 silicone-filled breast implants, giving surgeons and patients more options to achieve desired outcomes. [More]
Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Adults who are worried or terrified sometimes curl up into a fetal position. Likewise, adult cells that are injured, including genetic injury leading to cancer, initiate a process that was present during embryonic development. [More]
Inova Diagnostics announces FDA clearance for QUANTA Flash assays, QUANTA Flash Beta-2GP1 Domain1

Inova Diagnostics announces FDA clearance for QUANTA Flash assays, QUANTA Flash Beta-2GP1 Domain1

Inova Diagnostics, a worldwide leader in autoimmune diagnostic reagents and systems for the clinical laboratory, announced today that it has received 510(k) clearance by the U.S. Food and Drug Administration on key QUANTA Flash assays for use with Inova Diagnostics' BIO-FLASH chemiluminescent analyzer for autoimmune testing. [More]
Emory University immunologists identify long-lived antibody-producing cells in bone marrow

Emory University immunologists identify long-lived antibody-producing cells in bone marrow

Immunologists from Emory University have identified a distinct set of long-lived antibody-producing cells in the human bone marrow that function as an immune archive. [More]
Transplanted MSCs slow progression of lupus nephritis by suppressing Tfh cells in SLE animal model

Transplanted MSCs slow progression of lupus nephritis by suppressing Tfh cells in SLE animal model

Systemic lupus erythematosus (SLE) is an autoimmune disease that produces autoantibodies and subsequent immune reactions that can lead to a variety of symptoms, including inflammation of the kidneys, or nephritis. When researchers transplanted mesenchymal stem cells (MSCs) derived from human bone marrow into mice modeled with SLE, they found that inflammation was reduced and nephritis "attenuated." [More]
TSRI researchers awarded grant to study how environmental factors trigger autoimmune diseases

TSRI researchers awarded grant to study how environmental factors trigger autoimmune diseases

According to the U.S. Centers for Disease Control and Prevention, at least 1.5 million Americans suffer from rheumatoid arthritis and 322,000 have lupus, a chronic and potentially life-threatening disease that can damage skin, joints and organs. [More]
Bacterial biofilms play role in development of systemic lupus erythematosus

Bacterial biofilms play role in development of systemic lupus erythematosus

Lupus, multiple sclerosis, and type-1 diabetes are among more than a score of diseases in which the immune system attacks the body it was designed to defend. But just why the immune system begins its misdirected assault has remained a mystery. [More]
Researchers identify link between autoimmune diseases, medications and Long QT syndrome

Researchers identify link between autoimmune diseases, medications and Long QT syndrome

Mohamed Boutjdir, PhD, professor of medicine, cell biology, and physiology and pharmacology at SUNY Downstate Medical Center, has led a study with international collaborators identifying the mechanism by which patients with various autoimmune and connective tissue disorders may be at risk for life-threatening cardiac events if they take certain anti-histamine or anti-depressant medications. [More]
Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Both spouses and first-degree relatives of patients with celiac disease are at increased risk of nonceliac autoimmune disease, according to a study in the July issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. This risk represents a mixture of genetic, environmental and ascertainment bias mechanisms. [More]
Exhausted army of immune cells may damage the very body they are supposed to protect

Exhausted army of immune cells may damage the very body they are supposed to protect

An 'exhausted' army of immune cells may not be able to fight off infection, but if its soldiers fight too hard they risk damaging the very body they are meant to be protecting, suggests new research from the University of Cambridge. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
Malaria parasite protein essential for parasite invasion into red blood cells

Malaria parasite protein essential for parasite invasion into red blood cells

A new study led by researchers at Harvard T.H. Chan School of Public Health finds that a malaria parasite protein called calcineurin is essential for parasite invasion into red blood cells. Human calcineurin is already a proven target for drugs treating other illnesses including adult rheumatoid arthritis and lupus, and the new findings suggest that parasite calcineurin should be a focus for the development of new antimalarial drugs. [More]
University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

The Feinstein Institute for Medical Research and Molecular Medicine announced today that the fourth Anthony Cerami Award in Translational Medicine will be conferred to Thomas E. Starzl, MD, PhD, professor of surgery at the University of Pittsburgh School of Medicine. The award is in recognition of his research in organ transplantation and alloengraftment mechanisms. [More]
Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced that its common shares will begin trading on the NASDAQ Global Select Market on June 29, 2015 under the symbol CXRX. [More]
Advertisement
Advertisement